PEDIATRIC GUILLAIN-BARRÉ SYNDROME IN MÉXICO CLINICAL FEATURES BEFORE AND DURING SARS-COV-2 PANDEMIC

Authors

  • Fabiola Marycruz De la Fuente-Silva Instituto Mexicano del Seguro Social, Unidad Médica de Alta Especialidad Hospital General Centro Médico Nacional La Raza, ``Dr. Gaudencio González Garza´´, México City, México. https://orcid.org/0000-0001-7008-4754
  • Juan Antonio De la Fuente-Pineda Instituto Mexicano del Seguro Social, Hospital General Regional No. 25, México. https://orcid.org/0000-0001-7008-4754
  • Martín Arturo Silva-Ramírez Instituto Mexicano del Seguro Social, Unidad Médica de Alta Especialidad Hospital General Centro Médico Nacional La Raza, ``Dr. Gaudencio González Garza´´, México. https://orcid.org/0000-0001-7665-5466
  • Sofía Lucila Rodríguez-Rivera Instituto Mexicano del Seguro Social, Unidad Médica de Alta Especialidad Hospital General Centro Médico Nacional La Raza, ``Dr. Gaudencio González Garza´´, México. https://orcid.org/0000-0002-8679-7211
  • Ricardo Iván Montaño-González Universidad Tecnológica de México, México. https://orcid.org/0000-0001-7729-4092
  • Paula Ramírez-Palacios Unidad de Investigación Epidemiológica y en Servicios de Salud Instituto Mexicano del Seguro Social. Morelos, México. https://orcid.org/0000-0002-2586-4396

DOI:

https://doi.org/10.31157/an.v1iInpress.625

Keywords:

Guillain-Barré-Syndrome; pediatric; immunoglobulin; SARS-CoV-2; pandemic;

Abstract

Introduction: Guillain-Barré Syndrome is the most common cause of acute flaccid paralysis in childhood. It is a post infectious disease immune-mediated with a rapidly progressive course, usually without relapse. The main features are progressive weakness of more than one limb, areflexia or hyporeflexia, which gets progressively worst over days-to-weeks, to potentially life-threatening severity requiring mechanical ventilation.

Objective: We aimed to describe the clinical features of pediatric Guillain-Barré Syndrome in México before and during SARS-CoV-2 pandemic.

Methods: We performed an ambispective, observational, cross-sectional study in a Mexican reference hospital from January 2013 to December 2021. Data were obtained through records: demographic, clinical, laboratories, neurophysiological variants and treatment.

Results: Here we show that of the 96 patients, 55 were males with mean age of 9 years, 72% had history of infection; progressive weakness was present in 97%, areflexia/hyporeflexia 97%, progression of symptoms 99%, mean cells of 9/mm3 and mean proteins 88 mg/dL. Admission to Pediatric Intensive Care Unit was 20%. Acute Motor Axonal Neuropathy was the most frequent subtype. Nineteen patients required mechanical ventilation. Immunoglobulin was administered in 88%. Most frequent Disability Score at discharge was bedridden/wheelchair-bound. During 2020-2021 we found two SARS-CoV-2 cases and one associated with BNT162b2 vaccine.

Conclusions: Our results demonstrate that clinical features of pediatric Guillain-Barré Syndrome are similar before and during SARS-CoV-2 pandemic, nevertheless the number of cases associated with SARS-CoV-2 infection did not find increase.

Author Biographies

Fabiola Marycruz De la Fuente-Silva, Instituto Mexicano del Seguro Social, Unidad Médica de Alta Especialidad Hospital General Centro Médico Nacional La Raza, ``Dr. Gaudencio González Garza´´, México City, México.

Pediatric Neurology.

Juan Antonio De la Fuente-Pineda, Instituto Mexicano del Seguro Social, Hospital General Regional No. 25, México.

Internal Medicine with Training in Adult Neurology.

Martín Arturo Silva-Ramírez, Instituto Mexicano del Seguro Social, Unidad Médica de Alta Especialidad Hospital General Centro Médico Nacional La Raza, ``Dr. Gaudencio González Garza´´, México.

Pediatric Neurology

Sofía Lucila Rodríguez-Rivera, Instituto Mexicano del Seguro Social, Unidad Médica de Alta Especialidad Hospital General Centro Médico Nacional La Raza, ``Dr. Gaudencio González Garza´´, México.

Pediatric Neurology

Ricardo Iván Montaño-González, Universidad Tecnológica de México, México.

PhD in Chemicobiological Science.

Paula Ramírez-Palacios, Unidad de Investigación Epidemiológica y en Servicios de Salud Instituto Mexicano del Seguro Social. Morelos, México.

PhD in Epidemiology Science.

References

Guillain G BJSA. Sur un syndrome de radiculo-nevrite avec hyperalbuminose du liquide cephalorachidien sans reaction cellulaire. Remarques sur les caracteres cliniques et graphiques desrefl exes tendineux. Bull Soc Med Hop Paris 1916;28:1462–70.

Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. The Lancet 2016;388:717–27. https://doi.org/10.1016/S0140-6736(16)00339-1. DOI: https://doi.org/10.1016/S0140-6736(16)00339-1

Korinthenberg R, Schessl J, Kirschner J. Clinical presentation and course of childhood Guillain-Barré syndrome: a prospective multicentre study. Neuropediatrics 2007;38:10–7. https://doi.org/10.1055/S-2007-981686. DOI: https://doi.org/10.1055/s-2007-981686

Durán RA, Fonseca-Chon I, Sotelo-Cruz N. Guillain-Barré syndrome. Experience with 91 Children at a Pediatric Hospital in Northwestern Mexico. Arch Neurocien 2016:21(1):7-16. https://www.medigraphic.com/cgi-bin/new/resumenI.cgi?IDARTICULO=68277 (accessed May 19, 2022). DOI: https://doi.org/10.31157/an.v21i1.106

WHO. Coronavirus disease 2019 (2019-nCOV) Situation Report – 11. World Health Organization 2020:1–7.

Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol 2020;77:683–90. https://doi.org/10.1001/JAMANEUROL.2020.1127. DOI: https://doi.org/10.1001/jamaneurol.2020.1127

Ray STJ, Abdel-Mannan O, Sa M, Fuller C, Wood GK, Pysden K, et al. Neurological manifestations of SARS-CoV-2 infection in hospitalised children and adolescents in the UK: a prospective national cohort study. Lancet Child Adolesc Health 2021;5:631–41. https://doi.org/10.1016/S2352-4642(21)00193-0. DOI: https://doi.org/10.1016/S2352-4642(21)00193-0

IMSS. El Hospital General del CMN La Raza conmemora 67 años de su inauguración simbólica. IMSS 2019. http://www.imss.gob.mx/prensa/archivo/201910/423 (accessed August 17, 2023).

Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990;27 Suppl:S21–4. https://doi.org/10.1002/ANA.410270707. DOI: https://doi.org/10.1002/ana.410270707

Hughes RAC, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet 1978;2:750–3. https://doi.org/10.1016/S0140-6736(78)92644-2. DOI: https://doi.org/10.1016/S0140-6736(78)92644-2

Job KM, Gamalo M, Ward RM. Pediatric Age Groups and Approach to Studies. Ther Innov Regul Sci 2019;53:584–9. https://doi.org/10.1177/2168479019856572. DOI: https://doi.org/10.1177/2168479019856572

Nachamkin I, Barbosa PA, Ung H, Lobato C, Rivera AG, Rodriguez P, et al. Patterns of Guillain-Barré syndrome in children: Results from a Mexican population. Neurology 2007;69:1665–71. https://doi.org/10.1212/01.wnl.0000265396.87983.bd. DOI: https://doi.org/10.1212/01.wnl.0000265396.87983.bd

González-Rivera, Chico-Aldama, Arzate-Barbosa, Mario R-P, Cecilia L, Irving N, Viveros Wendy DD, et al. Epidemiología del síndrome de Guillain-Barré asociado a Campylobacter jejuni en el INP. Acta Pediatr Mex 2006;27:300–3.

Hurwitz ES, Schonberger LB, Nelson DB, Holman RC. Guillain-Barré syndrome and the 1978-1979 influenza vaccine. N Engl J Med 1981;304:1557–61. https://doi.org/10.1056/NEJM198106253042601. DOI: https://doi.org/10.1056/NEJM198106253042601

Grave C, Boucheron P, Rudant J, Mikaeloff Y, Tubert-Bitter P, Escolano S, et al. Seasonal influenza vaccine and Guillain-Barré syndrome: A self-controlled case series study. Neurology 2020;94:e2168–79. https://doi.org/10.1212/WNL.0000000000009180. DOI: https://doi.org/10.1212/WNL.0000000000009180

Kinnunen E, Junttila O, Haukka J, Hovi T. Nationwide oral poliovirus vaccination campaign and the incidence of Guillain-Barré Syndrome. Am J Epidemiol 1998;147:69–73. https://doi.org/10.1093/OXFORDJOURNALS.AJE.A009369. DOI: https://doi.org/10.1093/oxfordjournals.aje.a009369

Nasiri J, Ghazavi M, Yaghini O, Chaldavi M. Clinical Features and Outcome of Guillain-Barré Syndrome in Children. Iran J Child Neurol 2018;12:49–57. https://doi.org/10.22037/ijcn.v12i2.15159.

Ramos-Alvarez M, Bessudo L, Sabin AB. Paralytic Syndromes Associated With Noninflammatory Cytoplasmic or Nuclear Neuronopathy: Acute Paralytic Disease in Mexican Children, Neuropathologically Distinguishable From Landry-Guillain-Barré Syndrome. JAMA 1969;207:1481–92. https://doi.org/10.1001/JAMA.1969.03150210065008. DOI: https://doi.org/10.1001/jama.207.8.1481

Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol 2020;19:383–4. https://doi.org/10.1016/S1474-4422(20)30109-5. DOI: https://doi.org/10.1016/S1474-4422(20)30109-5

Xu E, Xie Y, Al-Aly Z. Long-term neurologic outcomes of COVID-19. Nature Medicine 2022 2022:1–10. https://doi.org/10.1038/s41591-022-02001-z. DOI: https://doi.org/10.21203/rs.3.rs-1473735/v1

Frank CHM, Almeida TVR, Marques EA, De Sousa Monteiro Q, Feitoza PVS, Borba MGS, et al. Guillain-Barré Syndrome Associated with SARS-CoV-2 Infection in a Pediatric Patient. J Trop Pediatr 2021;67. https://doi.org/10.1093/TROPEJ/FMAA044. DOI: https://doi.org/10.1093/tropej/fmaa044

Luijten LWG, Leonhard SE, van der Eijk AA, Doets AY, Appeltshauser L, Arends S, et al. Guillain-Barré syndrome after SARS-CoV-2 infection in an international prospective cohort study. Brain 2021;144:3392–404. https://doi.org/10.1093/BRAIN/AWAB279. DOI: https://doi.org/10.1093/brain/awab279

López-Hernández JC, Pérez-Valdez EY, León-Manríquez E, Bazán-Rodríguez L, Galnares-Olalde JA, Jorge-De Saráchaga A, et al. Guillain-Barre syndrome during COVID-19 pandemic: experience from a referral healthcare center in Mexico. Rev Neurol 2021;73:315–20. https://doi.org/10.33588/RN.7309.2021364. DOI: https://doi.org/10.33588/rn.7309.2021364

García-Grimshaw M, Michel-Chávez A, Vera-Zertuche JM, Galnares-Olalde JA, Hernández-Vanegas LE, Figueroa-Cucurachi M, et al. Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine. Clin Immunol 2021;230. https://doi.org/10.1016/J.CLIM.2021.108818. DOI: https://doi.org/10.1016/j.clim.2021.108818

Malamud E, Otallah SI, Caress JB, Lapid DJ. “Guillain-Barré Syndrome After COVID-19 Vaccination in an Adolescent” [Pediatric Neurology, Volume 126, January 2022, Pages 9-10]. Pediatr Neurol 2022;128:77. https://doi.org/10.1016/J.PEDIATRNEUROL.2021.11.001. DOI: https://doi.org/10.1016/j.pediatrneurol.2021.11.001

Published

2023-09-18

How to Cite

De la Fuente-Silva, F. M., De la Fuente-Pineda, J. A., Silva-Ramírez, M. A., Rodríguez-Rivera, S. L., Montaño-González, R. I., & Ramírez-Palacios, P. (2023). PEDIATRIC GUILLAIN-BARRÉ SYNDROME IN MÉXICO CLINICAL FEATURES BEFORE AND DURING SARS-COV-2 PANDEMIC. Archivos De Neurociencias, 1(Inpress). https://doi.org/10.31157/an.v1iInpress.625

Issue

Section

Original Articles